Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lantern PharmaLTRN -0.34%33 Return-on-Tangible-Equity is -266.85% as of Mar. 2026. GuruFocus rates LTRN with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,199 Biotechnology companies, Lantern Pharma ranks worse than 82.32% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Lantern Pharma's annualized net income for the quarter that ended in Mar. 2026 was $-13.32 Mil. Lantern Pharma's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $4.99 Mil. Therefore, Lantern Pharma's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -266.85%.
The historical rank and industry rank for Lantern Pharma's Return-on-Tangible-Equity or its related term are showing as below:
LTRN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -655.33 Med: -57.24 Max: -22.35
Current: -162.81
During the past 8 years, Lantern Pharma's highest Return-on-Tangible-Equity was -22.35%. The lowest was -655.33%. And the median was -57.24%.
LTRN's Return-on-Tangible-Equity is ranked worse than 82.32% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs LTRN: -162.81
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Lantern Pharma Return-on-Tangible-Equity Related Terms
Lantern Pharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Lantern Pharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTRN vs PDSB, AURX, TIL: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Lantern Pharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantern Pharma Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lantern Pharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Lantern Pharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -266.85% mean?
Lantern Pharma (LTRN) has a Return-on-Tangible-Equity of -266.85% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Lantern Pharma and its competitors. According to the industry distribution chart, Lantern Pharma ranks #987 out of 1199 companies in the Biotechnology industry, placing it in the top 82.3%.
Is Lantern Pharma's Return-on-Tangible-Equity too high?
Lantern Pharma's current Return-on-Tangible-Equity is -266.85%. Based on the distribution chart, Lantern Pharma ranks #987 out of 1199 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lantern Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Lantern Pharma's Return-on-Tangible-Equity compare to PDSB and AURX?
According to the Biotechnology industry distribution chart, Lantern Pharma ranks #987 out of 1199 companies for Return-on-Tangible-Equity. This places Lantern Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Lantern Pharma and its competitors. Lantern Pharma's current Return-on-Tangible-Equity is -266.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantern Pharma stock overvalued right now?
Lantern Pharma (LTRN) has a current Return-on-Tangible-Equity of -266.85%. The current Return-on-Tangible-Equity is -266.85%. Lantern Pharma's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Lantern Pharma (LTRN), the current Return-on-Tangible-Equity is -266.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
33GF Score
Get the complete analysis for LTRN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTRN has been successfully added to your 
